RASAL2 and breast carcinoma: For RASAL2, Mclaughlin reported elevated p-AKT levels in a mouse model of RASAL2-silenced mammary carcinoma [24]; however, Fang found that inhibition of RASAL2 in hepatocellular carcinoma was followed by a decrease in p-AKT levels [20], and our previous study demonstrated that RASAL2 regulated bladder cancer angiogenesis through p-AKT.